Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCAD versus oseltamivir in immunocompromised patients with influenza A
NL-OMON32856Phase 2Withdrawn
- Sponsor
- PRA Health Sciences
- Start
- Nov 2009
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of amantadine, ribavirin and oseltamivir in Influenza A infection (2 arms), sponsored by PRA Health Sciences. Primary endpoint: Clearing of viral shedding. Planned start Nov 2009; status: withdrawn.
02
Drugs
amantadineribavirinoseltamivir
03
Conditions
Influenza A infection
Beyond the preview
Go deeper on NL-OMON32856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32856.